#865
#866
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
#867
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
#868
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
#869
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
#870
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
#871
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
#872
Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Pharmaceuticals, Inc (THLD): Opiniones
MLV & Co raises their THLD tgt to $15.40 from $5 given the strongly positive Phase IIb results of TH-302 in front-line pancreatic cancer announced February 21, they believe the overall risk profile of THLD shares has decreased significantly, and have thus lowered their discount rate and raised price target accordingly.